Dimeric molecular complexes with free cysteine residues and conjugates thereof
OwnerDavid Light, Paul Szymanski +2inventors
InventorsDavid Light, Paul Szymanski, Marian Seto, Aline Cornelius
Life of this patent
Estimating the term…
Abstract
The invention relates generally to dimeric molecular complexes comprising two fusion proteins. Each fusion protein comprises a biological effector moiety, a polypeptide spacer sequence, and an IgE CH4 dimerization domain. The dimeric molecular complexes may be conjugated, at a defined site, to other molecules including drug moieties, cytotoxic agents, labels (such as detectable labels), or biocompatible polymers.
Claims45
A dimeric molecular complex comprising a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
- (A) a biological effector moiety selected from the group consisting of:
- (1) a single chain antibody;
- (2) an Fab fragment;
- (3) an extracellular domain of a type I membrane receptor;
- (4) a cytokine;
- (5) a chemokine;
- (6) an enzyme;
- and
- (7) a toxin;
- wherein at least one of the fusion proteins has a biological effector moiety that is a targeting biological effector moiety selected from the group consisting of (1) a single chain antibody;
- (2) an Fab fragment;
- (3) an extracellular domain of a type I membrane receptor;
- (4) a cytokine;
- (5) a chemokine;
- and (6) an enzyme;
- (B) a polypeptide spacer sequence;
- and
- (C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
- wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A dimeric molecular complex comprising a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
- (A) an IgE CH4 dimerization domain with a C terminal extension comprised of an M2″ extension of an IgE CH4 splice variant;
- (B) an amino acid spacer which is covalently bound to the IgE CH4 dimerization domain;
- and
- (C) an extracellular domain of a type II membrane receptor;
- wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues.
A nucleic acid molecule which encodes a fusion protein comprising from N to C terminus:
- (A) a biological effector moiety selected from the group consisting of:
- (1) a single chain antibody;
- (2) an Fab fragment;
- (3) an extracellular domain of a type I membrane receptor;
- (4) a cytokine;
- (5) a chemokine;
- (6) an enzyme;
- and
- (7) a toxin;
- (B) a polypeptide spacer sequence;
- and
- (C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
- wherein the fusion protein comprises one or more free cysteine amino acid residues.
(canceled)
(canceled)
A conjugate comprising a dimeric molecular complex coupled to a drug moiety, cytotoxic agent, label, or biocompatible polymer as shown in (I):
- D-La-M (I)
- wherein D is the dimeric molecular complex, L is a linker covalently attached to D at a free cysteine on D, M is a conjugate molecule selected from a drug moiety, cytotoxic agent, label, or biocompatible polymer, and a is 0 or 1 and further wherein the dimeric molecular complex comprises a first and a second fusion protein, wherein each fusion protein comprises from its N to C terminus:
- (A) a biological effector moiety selected from the group consisting of:
- (1) a single chain antibody;
- (2) an Fab fragment;
- (3) an extracellular domain of a type I membrane receptor;
- (4) a cytokine;
- (5) a chemokine;
- (6) an enzyme;
- and
- (7) a toxin;
- wherein at least one of the fusion proteins has a biological effector moiety that is a targeting biological effector moiety selected from the group consisting of (1) a single chain antibody;
- (2) an Fab fragment;
- (3) an extracellular domain of a type I membrane receptor;
- and (4) an enzyme;
- (B) a polypeptide spacer sequence;
- and
- (C) a CH4 dimerization domain of an IgE molecule covalently bound to the polypeptide spacer sequence;
- wherein the molecular complex comprises at least one disulfide bond between a cysteine residue in the first fusion protein and a cysteine residue in the second fusion protein, and at least one of the fusion proteins comprises one or more free cysteine amino acid residues that reacts with the linker to form the conjugate or, if a is 0, reacts with the conjugate molecule to form the conjugate.
(canceled)
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.